On the afternoon of January 11th, Jiang Zhuoqing, Chairman of the Standing Committee of Shanghai Municipal People's Congress, led a team to visit and investigate the Yangtze River Delta Pharmaceutical Innovation and Development Alliance (hereinafter referred to as the "Alliance"), and listened to the report of relevant units of the Alliance.
At the meeting, the Alliance reported its establishment and recent work plan. Sun Piaoyang, Chairman of Hengrui Pharmaceuticals, Li Jia, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wu Hao, Co-President of Tigermed, Chen Bingliang, Chief Scientist of Innovent Bio, and other alliance sponsors conducts in-depth exchanges and discussions on a number of key issues such as collective sourcing of innovative drugs and market-oriented pricing, medical insurance payment system reform and commercial insurance development, pharmaceutical source innovation, commercialization of scientific and technological results, regional ethical integration, and the "last mile" of innovative drug admission, as well as related policy support suggestions.
Mr. Jiang pointed out that it is necessary to thoroughly implement the national strategy of high-quality integrated development in the Yangtze River Delta and the work requirements of CPC Shanghai Municipal Committee. Relying on the characteristics and advantages of Shanghai's biomedical resources, we should give full play to the role of innovation platform and research think tank of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance, take the biomedical industry chain as a link, effectively integrate and gather various innovative resources, and promote the deep integration of biomedical production, education and research in the Yangtze River Delta region. It is important to adhere to the problem orientation, deepen research around the bottleneck problems affecting the innovation and development of biomedical industry, and put forward opinions and suggestions to promote industrial development. Shanghai Biomedical Industry Promotion Task Force should strengthen interfacing, provide active services and continuously optimize the business environment for the development of biomedical industry.
Zhao Weixing, Secretary General of the Standing Committee of Shanghai Municipal People's Congress, Dai Liu, Chairman of the Financial and Economic Committee of Shanghai Municipal People's Congress, and Liu Ping, Vice Chairman of Shanghai Municipal Commission of Economy and Informatization, participated in the investigation.
